Form 4: Oramed Pharmaceuticals Director Daniel Aghion Receives Significant RSU Grants, Boosting Equity Alignment

Oramed Pharmaceuticals Inc. director Daniel Aghion was granted 38,371 Restricted Stock Units (RSUs) on June 5, 2025, aligning his interests with shareholders through future equity vesting.

Summary

• Daniel Aghion, a Director of Oramed Pharmaceuticals Inc. (ORMP), reported changes in his beneficial ownership via a Form 4 filing.
• On June 5, 2025, Mr. Aghion acquired 30,000 Restricted Stock Units (RSUs).
• These 30,000 RSUs are scheduled to vest in three equal portions of 10,000 shares on January 1, 2026, January 1, 2027, and January 1, 2028.
• Additionally, on the same date, Mr. Aghion acquired another 8,371 RSUs.
• These 8,371 RSUs will vest in equal installments on the grant date (June 5, 2025), July 1, 2025, October 1, 2025, and January 1, 2026.
• All RSUs convert into the Issuer's Common Stock on a one-for-one basis.
• Following these transactions, Daniel Aghion directly beneficially owns a total of 77,191 shares of Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the RSU grants align the director's interests with shareholders, which is generally viewed favorably. It's a routine compensation event, not indicative of major operational changes.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns management's long-term interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a common and effective way to incentivize directors and retain talent.

Future Outlook

The future outlook indicates that Daniel Aghion will receive additional shares of Oramed Pharmaceuticals Common Stock as his Restricted Stock Units vest according to the specified schedules through January 2028, contingent on his continued service.

Industry Context

This filing reflects a common practice in the pharmaceutical and biotechnology industry, where equity compensation, such as Restricted Stock Units, is frequently used to compensate directors and executives. This method helps align the interests of company leadership with long-term shareholder value creation, which is particularly relevant in industries with long development cycles and high R&D costs.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of compensation for directors is a standard practice across publicly traded companies, including those in the pharmaceutical sector like Oramed Pharmaceuticals Inc.
• This approach is consistent with compensation strategies observed in comparable companies such as Pfizer Inc. (PFE), Moderna, Inc. (MRNA), and BioNTech SE (BNTX), where equity awards are a significant component of executive and director remuneration to incentivize performance and retention.

Stakeholder Impact

• Shareholders: The RSU grants align the director's financial interests with the long-term performance of the company, potentially leading to more shareholder-friendly decisions.
• Employees: While not directly impacting general employees, the compensation structure for leadership can set a precedent for performance-based incentives across the organization.

Next Steps

• Vesting of 10,000 RSUs on January 1, 2026.
• Vesting of a portion of 8,371 RSUs on July 1, 2025, October 1, 2025, and January 1, 2026.
• Vesting of 10,000 RSUs on January 1, 2027.
• Vesting of 10,000 RSUs on January 1, 2028.

Key Dates

Keywords

Oramed Pharmaceuticals, ORMP, SEC Form 4, Restricted Stock Units, RSUs, Insider Transaction, Beneficial Ownership, Director Compensation, Equity Compensation, Stock Grant, Vesting Schedule